[ 18 F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma.

MLA

Vos, Joris L., et al. “[ 18 F]FDG-PET Accurately Identifies Pathological Response Early upon Neoadjuvant Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.” European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 6, May 2022, pp. 2010–22. EBSCOhost, https://doi.org/10.1007/s00259-021-05610-x.

APA

Vos, J. L., Zuur, C. L., Smit, L. A., de Boer, J. P., Al-Mamgani, A., van den Brekel, M. W. M., Haanen, J. B. A. G., & Vogel, W. V. (2022). [ 18 F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 49(6), 2010–2022. https://doi.org/10.1007/s00259-021-05610-x

Chicago

Vos, Joris L, Charlotte L Zuur, Laura A Smit, Jan Paul de Boer, Abrahim Al-Mamgani, Michiel W M van den Brekel, John B A G Haanen, and Wouter V Vogel. 2022. “[ 18 F]FDG-PET Accurately Identifies Pathological Response Early upon Neoadjuvant Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.” European Journal of Nuclear Medicine and Molecular Imaging 49 (6): 2010–22. doi:10.1007/s00259-021-05610-x.